Reflections on the Cost of "Low-Cost" Whole Genome Sequencing: Framing the Health Policy Debate
Open Access
- 5 November 2013
- journal article
- perspective
- Published by Public Library of Science (PLoS) in PLoS Biology
- Vol. 11 (11), e1001699
- https://doi.org/10.1371/journal.pbio.1001699
Abstract
The cost of whole genome sequencing is dropping rapidly. There has been a great deal of enthusiasm about the potential for this technological advance to transform clinical care. Given the interest and significant investment in genomics, this seems an ideal time to consider what the evidence tells us about potential benefits and harms, particularly in the context of health care policy. The scale and pace of adoption of this powerful new technology should be driven by clinical need, clinical evidence, and a commitment to put patients at the centre of health care policy.This publication has 33 references indexed in Scilit:
- The next controversy in genetic testing: clinical data as trade secrets?European Journal of Human Genetics, 2012
- Evaluating genomic tests from bench to bedside: a practical frameworkBMC Medical Informatics and Decision Making, 2012
- After the revolution? Ethical and social challenges in ‘personalized genomic medicine’Personalized Medicine, 2012
- To hype, or not to(o) hypeEMBO Reports, 2012
- No evidence of association between complement factor I genetic variant rs10033900 and age-related macular degenerationEuropean Journal of Human Genetics, 2011
- Whole-Genome Sequencing for Optimized Patient ManagementScience Translational Medicine, 2011
- Effect of Direct-to-Consumer Genomewide Profiling to Assess Disease RiskThe New England Journal of Medicine, 2011
- Effects of communicating DNA-based disease risk estimates on risk-reducing behavioursEmergencias, 2010
- Cancer genome sequencing: a reviewHuman Molecular Genetics, 2009
- Why Current Publication Practices May Distort SciencePLoS Medicine, 2008